U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
Andrew Villani Traci Mccarty Biomarin Rareconnections Hank Fuchs William Wilcox Committee For Medicinal Products Human Use
Source: prnewswire.com